Sigrid Skanland

Title: Sigrid Skanland: Innovator in Cancer Treatment

Introduction

Sigrid Skanland is a prominent inventor based in Oslo, Norway. She has made significant contributions to the field of cancer treatment, particularly through her innovative research on ALK inhibitors. Her work focuses on addressing ALK-negative cancers and plasma cell-mediated diseases, which are critical areas in oncology.

Latest Patents

Sigrid holds 1 patent for her invention titled "ALK inhibitors for treatment of ALK-negative cancer and plasma cell-mediated diseases." This patent presents a method for treating ALK-negative/LTK-positive cancer by administering a pharmaceutically effective dose of a linear inhibitor of ALK. The invention is especially useful in treating multiple myeloma, including cases resistant to proteasome inhibitors.

Career Highlights

Sigrid is affiliated with the University of Oslo, where she conducts her research and develops her innovative treatments. Her academic background and dedication to cancer research have positioned her as a key figure in the scientific community.

Collaborations

Sigrid collaborates with notable colleagues, including Hesso Farhan and Ludvig Munthe. Their combined expertise enhances the research efforts at the University of Oslo and contributes to advancements in cancer treatment.

Conclusion

Sigrid Skanland's work in developing ALK inhibitors represents a significant advancement in the treatment of ALK-negative cancers. Her contributions to oncology are invaluable, and her ongoing research continues to inspire hope for patients facing these challenging diseases.